{Reference Type}: Journal Article
{Title}: Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals.
{Author}: Ettienne EB;Russo E;Striano P;Grant-Kels JM;Rose K;
{Journal}: World J Methodol
{Volume}: 14
{Issue}: 2
{Year}: 2024 Jun 20
暂无{DOI}: 10.5662/wjm.v14.i2.92371
{Abstract}: Modern drugs have changed epilepsy, which affects people of all ages. However, for young people with epilepsy, the framework of drug development has stalled. In the wake of the thalidomide catastrophe, the misconception emerged that for people < 18 years of age drugs, including antiseizure medications (ASMs), need separate proof of efficacy and safety, overall called "pediatric drug development". For ASMs, this has changed to some degree. Authorities now accept that ASMs are effective in < 18 years as well, but they still require "extrapolation of efficacy," as if minors were another species. As a result, some of the pediatric clinical epilepsy research over the past decades was unnecessary. Even more importantly, this has hampered research on meaningful research goals. We do not need to confirm that ASMs work before as they do after the 18th birthday. Instead, we need to learn how to prevent brain damage in young patients by preventing seizures and optimize ASMs' uses. Herein we discuss how to proceed in this endeavor.